Landscapes / Companies
EMD Serono not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs1
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Merck KGaA, Darmstadt, Germany |
Approved | — | ||
| How it works | Blocks a kinase | ||||
| Also tested for | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021